ANI Pharmaceuticals (ANIP) Set to Post Quarterly Earnings on Thursday

ANI Pharmaceuticals (NASDAQ:ANIP) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $2.18 per share and revenue of $280.26 million for the quarter. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.80 earnings per share. On average, analysts expect ANI Pharmaceuticals to post $7.76 EPS for the current fiscal year and $8.32 EPS for the next fiscal year.

ANI Pharmaceuticals Stock Up 0.8%

Shares of NASDAQ:ANIP opened at $71.71 on Thursday. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The business has a fifty day moving average of $73.16 and a two-hundred day moving average of $77.75. The stock has a market cap of $1.65 billion, a P/E ratio of 15.45, a PEG ratio of 2.34 and a beta of 0.50. ANI Pharmaceuticals has a 52-week low of $69.58 and a 52-week high of $95.57.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 3,162 shares of ANI Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was sold at an average price of $77.00, for a total value of $243,474.00. Following the sale, the senior vice president owned 75,534 shares in the company, valued at $5,816,118. The trade was a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $71.89, for a total value of $388,206.00. Following the completion of the sale, the chief executive officer owned 333,689 shares in the company, valued at $23,988,902.21. This represents a 1.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 27,562 shares of company stock valued at $2,013,290 in the last ninety days. Company insiders own 8.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on ANIP shares. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Oppenheimer initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 price objective for the company. Canaccord Genuity Group cut their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 9th. They set an “outperform” rating and a $104.00 target price on the stock. Three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $99.60.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.